Merck to invest $70m for R&D facility expansion in Massachusetts
Category: #health  By Mateen Dalal  Date: 2019-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck to invest $70m for R&D facility expansion in Massachusetts

The building construction is scheduled to be completed in 2021 and is designed to offer office space, wet labs and a cafeteria.

Merck, one of the leaders in the pharmaceutical industry recently announced that it will be investing $70 million for the expansion of its R&D facility in Massachusetts. The new building will reportedly cover an area of 145,000 square feet and offer collaborative working and laboratory space for the 400 new and current R&D employees. The research and development activities will be focused on immunology, immuno-oncology and oncology.

Luciano Rossetti, Head of Global R&D at Biopharma business, Merck, has been quoted to say that the passionate and talented R&D teams in Billerica, Massachusetts are intensely engaged in advancing various pipeline compounds. He added that Merck continues to strengthen its innovation footprint in Darmstadt, Germany where its global R&D headquarters are located besides expanding in the U.S., aiming to deliver transformational value to patients across the globe.

Reliable sources report that with the latest development, Merck’s investment in infrastructure will cross $150 million in biopharmaceutical R&D advancement in Massachusetts. Such advancements have led to the creation of more than 150 new jobs ever since the Billerica R&D Hub was founded in 2011. The town of Billerica worked collaboratively with company officials and played a key role in the fruition of the latest building expansion project by underscoring the advantages of state-of-the-art R&D facility expansion.

Travis McCready, CEO and President of the Massachusetts Life Sciences Center reportedly said that by continual investment in the state of Massachusetts Merck has become a testament to the state's global leadership in life sciences. He added that in collaboration with the town of Billerica, the company has not only succeeded in retaining top talent in the area but also significantly contributed towards improving the lives of people with serious medical needs.

The building construction is scheduled to be completed in 2021 and is designed to offer office space, wet labs and a cafeteria. The building will have LEED® and WELL certifications and conform to environmental and employee wellness standards.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZenecas Farxiga gets fast track status to treat heart failure
AstraZenecas Farxiga gets fast track status to treat heart failure
By Mateen Dalal

With heart related issues and number of people diagnosed with heart failure increasing substantially, the need to find a solution to this problem is growing considerably. Advanced technology, equipment and pharmaceutical companies are continuously wo...

Upstream Works, Aceyus to pioneer customer experience solutions
Upstream Works, Aceyus to pioneer customer experience solutions
By Mateen Dalal

Customer Experience (CX) is vital for companies to understand the mindset of their clients. Industries are actively investing in customer experience solutions to stay ahead in competition. Companies are also partnering with other market players to en...

Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
By Mateen Dalal

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB. In the company’s HORIZON trial, a cumulative response rate of 23% was attained with dexamethasone and mel...